Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer

References

• National Comprehensive Cancer Network IncNCCN Clinical Practice Guidelines in OncologyBreast Cancer Version 2Fort Washington, PANCCN2015
   Google Scholar
• CardosoFCostaANortonL1st International consensus guidelines for advanced breast cancer (ABC 1)Breast201221324225222425534
   PubMed Web of Science ®Google Scholar
• BonneterreJBuzdarANabholtzJMArimidex Writing CommitteeInvestigators Committee MembersAnastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinomaCancer20019292247225811745278
   PubMed Web of Science ®Google Scholar
• CardosoFHarbeckNFallowfieldLKyriakidesSSenkusEESMO Guidelines Working GroupLocally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201223suppl 7vii11vii1922997442
   PubMed Web of Science ®Google Scholar
• Harichand-HerdtSZelnakAO’ReganREndocrine therapy for the treatment of postmenopausal women with breast cancerExpert Rev Anticancer Ther20099218719819192957
   PubMed Web of Science ®Google Scholar
• McArthurHLMorrisPGAromatase inhibitor strategies in metastatic breast cancerInt J Womens Health20101677221072276
   PubMedGoogle Scholar
• PalumboRSottotettiFRiccardiAWhich patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for cliniciansTher Adv Med Oncol20135633435024179488
   PubMed Web of Science ®Google Scholar
• WilsonSChiaSKTreatment algorithms for hormone receptor-positive advanced breast cancerAm Soc Clin Oncol Educ Book2013
   Google Scholar
• CardosoFBischoffJBrainEA review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal womenCancer Treat Rev201339545746522840697
   PubMed Web of Science ®Google Scholar
• American Society of Clinical OncologyThe state of cancer care in America, 2014: a report by the American Society of Clinical OncologyJ Oncol Pract201410211914224618075
   PubMedGoogle Scholar
• ShanafeltTDGradisharWJKostyMBurnout and career satisfaction among US oncologistsJ Clin Oncol201432767868624470006
   PubMed Web of Science ®Google Scholar
• DeschCEBlayneyDWMaking the choice between academic oncology and community practice: the big picture and details about each careerJ Clin Oncol20062132138
   Google Scholar
• LippmanAJGallinsonDJohnstoneDClinical practice issues in oncology impacted by healthcare reformMD Advis2012536822759868
   PubMedGoogle Scholar
• UllmanKOncologist practice consolidation continues: driven by changes in reimbursement and standards of care, independent community oncology practices continue to dwindleAm J Manag Care2012185 SpecS236
   Google Scholar
• TetreaultSAHarwinWNEagleD‘Economies of scale’ yield multiple benefits for a private, physician-run oncology practiceOncology (Williston Park)2013277616618C323977753
   PubMed Web of Science ®Google Scholar
• GnantMOvercoming endocrine resistance in breast cancer: importance of mTOR inhibitionExpert Rev Anticancer Ther201212121579158923253223
   PubMed Web of Science ®Google Scholar
• ChangJFanWEndocrine therapy resistance: current status, possible mechanisms and overcoming strategiesAnticancer Agents Med Chem201313346447522931419
   PubMed Web of Science ®Google Scholar
• ChlebowskiRTStrategies to overcome endocrine therapy resistance in hormone receptor-positive advanced breast cancerClin Invest201441933
   Google Scholar
• OsborneCKSchiffRMechanisms of endocrine resistance in breast cancerAnnu Rev Med20116223324720887199
   PubMed Web of Science ®Google Scholar
• ChlebowskiRTChanging concepts of hormone receptor-positive advanced breast cancer therapyClin Breast Cancer201313315916623228361
   PubMed Web of Science ®Google Scholar
• Garcia-BecerraRSantosNDiazLCamachoJMechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistanceInt J Mol Sci201214110814523344024
   PubMed Web of Science ®Google Scholar
• ErolesPBoschABermejoBLluchAMechanisms of resistance to hormonal treatment in breast cancerClin Transl Oncol201012424625220462833
   PubMed Web of Science ®Google Scholar
• XuYSunQHeadway in resistance to endocrine therapy in breast cancerJ Thorac Dis20102317117722263039
   PubMedGoogle Scholar
• TinocoGWarschSGluckSAvanchaKMonteroAJTreating breast cancer in the 21st century: emerging biological therapiesJ Cancer20134211713223386910
   PubMed Web of Science ®Google Scholar
• GluckSExtending the clinical benefit of endocrine therapy for women with hormone receptor-positive metastatic breast cancer: differentiating mechanisms of actionClin Breast Cancer2014142758424355138
   PubMed Web of Science ®Google Scholar
• Faslodex (fulvestrant) injection [package insert]Wilmington, DEAstraZeneca Pharmaceuticals LP2012
   Google Scholar
• Afinitor (everolimus) tablets for oral administrationAfinitor Disperz (everolimus tablets for oral suspension) [package insert]East Hanover, NJNovartis Pharmaceuticals Corp2016
   Google Scholar
• RobertsonJFOsborneCKHowellAFulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trialsCancer200398222923812872340
   PubMed Web of Science ®Google Scholar
• di LeoAJerusalemGPetruzelkaLResults of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancerJ Clin Oncol201028304594460020855825
   PubMed Web of Science ®Google Scholar
• di LeoAJerusalemGPetruzelkaLFinal overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trialJ Natl Cancer Inst20141061djt33724317176
   PubMedGoogle Scholar
• BaselgaJCamponeMPiccartMEverolimus in postmenopausal hormone receptor-positive advanced breast cancerN Engl J Med2012366652052922149876
   PubMed Web of Science ®Google Scholar
• YardleyDANoguchiSPritchardKIEverolimus plus exemestane in postmenopausal patients with HR breast cancer: BOLERO-2 final progression-free survival analysisAdv Ther2013301087088424158787
   PubMed Web of Science ®Google Scholar
• PiccartMHortobagyiGNCamponeMEverolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2Ann Oncol201425122357236225231953
   PubMed Web of Science ®Google Scholar
• BeckJTHortobagyiGNCamponeMEverolimus plus exemestane as first-line therapy in HR, HER2 advanced breast cancer in BOLERO-2Breast Cancer Res Treat2014143345946724362951
   PubMed Web of Science ®Google Scholar
• CamponeMLebrunFNoguchiSEfficacy of everolimus plus exemestane in patients who received prior chemotherapy for advanced breast cancer or recurred after adjuvant endocrine therapy in BOLERO-2Presented at: the American Society of Clinical Oncology Annual MeetingMay 31–June 4, 2013Chicago, IL, USA
   Google Scholar
• CamponeMBachelotTGnantMEffect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 studyEur J Cancer201349122621263223735704
   PubMed Web of Science ®Google Scholar
• YardleyDAIsmail-KhanRRMelicharBRandomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitorJ Clin Oncol2013312128213523650416
   PubMed Web of Science ®Google Scholar
• Ibrance (palbociclib) capsules, for oral use [package insert]New York, NYPfizer Labs2015
   Google Scholar
• FinnRSCrownJPLangIThe cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 studyLancet Oncol2015161253525524798
   PubMed Web of Science ®Google Scholar
• TurnerNCRoJAndreFPalbociclib in hormone-receptor-positive advanced breast cancerN Engl J Med2015373320921926030518
   PubMed Web of Science ®Google Scholar
• LlombartARavaioliAStraussLRandomized phase II study of dasatinib vs placebo in addition to exemestane in advanced ER/PR-positive breast cancer [BMS CA180-261 Study]Presented at: the San Antonio Breast Cancer SymposiumDecember 6–10, 2011San Antonio, TX, USA
   Google Scholar
• TrinhXBSasLVan LaereSJA phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancerOncol Rep201227365766322134540
   PubMed Web of Science ®Google Scholar
• GutteridgeEAgrawalANicholsonRLeungCKRobertsonJGeeJThe effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: a phase II studyInt J Cancer201012681806181619739079
   PubMed Web of Science ®Google Scholar
• CarlsonRWO’NeillAVidaurreTGomezHLBadveSSSledgeGWA randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancerBreast Cancer Res Treat201213331049105622418699
   PubMed Web of Science ®Google Scholar
• CristofanilliMValeroVMangalikAPhase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancerClin Cancer Res20101661904191420215537
   PubMed Web of Science ®Google Scholar
• OsborneCKNevenPDirixLYGefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II studyClin Cancer Res20111751147115921220480
   PubMed Web of Science ®Google Scholar
• SiegfriedJMGubishCTRothsteinMEHenryCStabileLPCombining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancerJ Thorac Oncol20127348549522258476
   PubMed Web of Science ®Google Scholar
• ClemonsMJCochraneBPondGRRandomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY studyBreast Cancer Res Treat2014146115316224924416
   PubMed Web of Science ®Google Scholar
• TrainaTARugoHSCaravelliJFFeasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancerJ Clin Oncol201028462863319841327
   PubMed Web of Science ®Google Scholar
• YardleyDABurrisHA3rdClarkBLHormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research ConsortiumClin Breast Cancer201111314615221665134
   PubMed Web of Science ®Google Scholar
• MartinMLoiblSvon MinckwitzMGPhase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) studyJ Clin Oncol20153391045105225691671
   PubMed Web of Science ®Google Scholar
• BuijsCde VriesEGMouritsMJWillemsePHThe influence of endocrine treatments for breast cancer on health-related quality of lifeCancer Treat Rev200834764065518514425
   PubMed Web of Science ®Google Scholar
• GibsonLJDawsonCKLawrenceDHBlissJMAromatase inhibitors for treatment of advanced breast cancer in postmenopausal womenCochrane Database Syst Rev2009CD00337019821307
   PubMed Web of Science ®Google Scholar
• MortimerJEManaging the toxicities of the aromatase inhibitorsCurr Opin Obstet Gynecol2010221566020019610
   PubMed Web of Science ®Google Scholar
• FallowfieldLJBlissJMPorterLSQuality of life in the inter-group exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancerJ Clin Oncol200624691091716484701
   PubMed Web of Science ®Google Scholar
• LonningPEikesdalHPAromatase inhibition 2013: clinical state of the art and questions that remain to be solvedEndocr Relat Cancer2013204R183R20123625614
   PubMed Web of Science ®Google Scholar
• LoprinziCLSloanJAPerezEAPhase III evaluation of fluoxetine for treatment of hot flashesJ Clin Oncol20022061578158311896107
   PubMed Web of Science ®Google Scholar
• LoprinziCLSloanJStearnsVNewer antidepressants and gabapentin for hot flashes: an individual patient pooled analysisJ Clin Oncol200927172831283719332723
   PubMed Web of Science ®Google Scholar
• StearnsVBeebeKLIyengarMDubeEParoxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trialJAMA2003289212827283412783913
   PubMed Web of Science ®Google Scholar
• LoprinziCLKuglerJWBartonDLPhase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5J Clin Oncol200725330831217146104
   PubMed Web of Science ®Google Scholar
• KligmanLYounusJManagement of hot flashes in women with breast cancerCurr Oncol2010171818620179808
   PubMed Web of Science ®Google Scholar
• GnantMRole of bisphosphonates in postmenopausal women with breast cancerCancer Treat Rev201440347648423906846
   PubMed Web of Science ®Google Scholar
• BoscoDOsteoporosis and aromatase inhibitors: experience and future prospectsClin Cases Miner Bone Metab201292899123087717
   PubMedGoogle Scholar
• Prolia (denosumab) injection, for subcutaneous use [package insert]Thousand Oaks, CAAmgen Inc2015
   Google Scholar
• FlemmingJMadarnasYFranekJAFulvestrant for systemic therapy of locally advanced or metastatic breast cancer in postmenopausal women: a systematic reviewBreast Cancer Res Treat2009115225526818683044
   PubMed Web of Science ®Google Scholar
• PortaCOstantoSRavaudAManagement of adverse events associated with the use of everolimus in patients with advanced renal cell carcinomaEur J Cancer2011471287129821481584
   PubMed Web of Science ®Google Scholar
• PilotteAPHohosMBPolsonKMHuftalenTMTreisterNManaging stomatitis in patients treated with Mammalian target of rapamycin inhibitorsClin J Oncol Nurs2011155E83E8921951751
   PubMedGoogle Scholar
• EisenTSternbergCNRobertCTargeted therapies for renal cell carcinoma: review of adverse event management strategiesJ Natl Cancer Inst201210429311322235142
   PubMed Web of Science ®Google Scholar
• RugoHSPritchardKIGnantMIncidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2Ann Oncol201425480881524615500
   PubMed Web of Science ®Google Scholar
• WhiteDACamusPEndoMNoninfectious pneumonitis after everolimus therapy for advanced renal cell carcinomaAm J Respir Crit Care Med2010182339640320194812
   PubMed Web of Science ®Google Scholar
• AaproMAndreFBlackwellKAdverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancerAnn Nutr Metab2014254763773
   Google Scholar